Pay-For-Delay Deals Drop In FY 2013; 10 Settlements May Undergo Further Analysis
Executive Summary
Of 145 brand-generic patent settlements in FY 2013, 29 contained both compensation to a generic manufacturer and a restriction on generic entry, down from 40 the previous year; compensation is uncertain in 10 additional deals.
You may also be interested in...
FTC vs. AbbVie Pay-For-Delay Suit Crafted For Supreme Court’s ‘Red Flag’ Test
But for the first time ever, Federal Trade Commissioners were split on whether to bring such a case; newer members voted ‘no.’
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits
Justices rule FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers, but Actavis pledges to continue defending these deals.
“Pay-For-Delay” Fight Is Now: FTC, GPhA Spar Over Report In Prelude To Supreme Court Review
Of the 140 brand-generic patent settlements in FY 2012, 40 contained both compensation to the generic manufacturer and a restriction on generic entry; FTC announces this record number as its suit against Watson goes to Supreme Court.